<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614050</url>
  </required_header>
  <id_info>
    <org_study_id>Multicenter-CRP</org_study_id>
    <nct_id>NCT05614050</nct_id>
  </id_info>
  <brief_title>HsCRP in the Prognosis of Patients After PCI：a Multi-center Study</brief_title>
  <official_title>High-sensitivity C-reactive Protein (hsCRP) in the Prognosis of Patients After Coronary Intervention (PCI) : a Multi-center Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Cardiovascular Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangyang First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yichang Central People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jingzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Wuhan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Hospital in Wuhan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital West Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital Jinyinhu Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary heart disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to&#xD;
      coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly&#xD;
      improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI),&#xD;
      these patients are still at high risk of major adverse cardiovascular and cerebrovascular&#xD;
      events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused&#xD;
      widespread concern. RIR is an important independent risk in patients with CAD. Previous&#xD;
      studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European&#xD;
      and American people. In China, the impact of dynamic changes of hsCRP on MACCE in PCI&#xD;
      population remains unclear. Therefore, in this study, the investigators plan to recruit&#xD;
      patients undergoing PCI, and observe the impact of RIR by serial hsCRP measurements on the&#xD;
      prognosis of these patients followed up for 1 years at 14 hospitals in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2022</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>12 months</time_frame>
    <description>A composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, ischemia-driven revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nonfatal myocardial infarction</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of nonfatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nonfatal stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of of nonfatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemia-driven revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of ischemia-driven revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization for unstable angina</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of hospitalization for unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent/scaffold thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of stent/scaffold thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-stent restenosis</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of in-stent restenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of bleeding</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>hsCRP</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma and whole blood cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The hospitalized patients with coronary heart disease completing all planned PCI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who understand and sign the informed consent voluntarily;&#xD;
&#xD;
          -  Age ≥ 18 years old and ≤ 80 years old, regardless of sex;&#xD;
&#xD;
          -  The hospitalized patients with coronary heart disease undergoing PCI;&#xD;
&#xD;
          -  Complete all planned PCI during hospitalization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute, chronic or recurrent infectious diseases;&#xD;
&#xD;
          -  Immune diseases or immune-related diseases;&#xD;
&#xD;
          -  Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and&#xD;
             chemotherapy drugs;&#xD;
&#xD;
          -  Pregnant women, lactating women or women of childbearing age who do not use effective&#xD;
             contraceptive measures;&#xD;
&#xD;
          -  The researchers determined that other conditions in which the patient was not suitable&#xD;
             to participate in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Xiang Cheng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miao Yu</last_name>
    <phone>+862785726009</phone>
    <email>yumiaodavid@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Cheng, Doctor</last_name>
      <phone>+8602785726011</phone>
      <email>nathancx@hust.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiang Cheng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 6, 2022</study_first_submitted>
  <study_first_submitted_qc>November 6, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>February 6, 2023</last_update_submitted>
  <last_update_submitted_qc>February 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Xiang Cheng</investigator_full_name>
    <investigator_title>Director of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

